Vimarsana
Biggest News Aggregation in the World

Page 42 - Zai Lab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Zai Lab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Zai Lab Today - Breaking & Trending Today

DeVry University Launches AI Lab to Advance Learner Success - Vimarsana News

DeVry University Launches AI Lab to Advance Learner Success

/PRNewswire/ -- DeVry University announced today the launch of its unique Artificial Intelligence (AI) Lab to help transform academic potential into academic...

Leading Independent Proxy Advisory Firm ISS Recommends - Vimarsana News

Leading Independent Proxy Advisory Firm ISS Recommends

BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (

Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients Wi - Vimarsana News

Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients Wi

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who received TIVDAK® (tisotumab vedoti...

Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve - Vimarsana News

Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve

Company AnnouncementPhase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival (OS) at predetermined, independent interim analysisTrial results to be submitted for presentation at a future medical meetingGenmab and Seagen to engage in discussions with regulatory authoritiesCOPENHAG...

Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results - Vimarsana News

Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results

Zai Lab Ltd.’s American depositary receipts jumped 14% premarket on Tuesday after Seagen Inc. and Genmab A/S announced that Tivdak, their treatment for...